Efficacy and Safety of Cilostazol for the Indication of CSPS

Otsuka

Status: Completed

Conditions: Cerebral Infarction

Study type: Observational

Funder types: Industry

Identifiers

NCT00216749

Korea Pletaal CSPS PMS

Details and patient eligibility

About

This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.

Full description

This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction.

Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.

Enrollment: 650 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with an experience of cerebral infarction and having a purpose for prevention of recurrence of cerebral infarction.
• Age: more than 18 years of age

Exclusion criteria

• Unqualified patients judged by study investigator(s)

Trial design

650 participants in 1 patient group

Cilostazol

Description:

Cilostazol Treatment Patients who were in stable states after the occurrence of cerebral infarction (except cardiogenic cerebral embolism)